Combination of immunotherapy and VEGF inhibitor improves survival in HCC

(European Society for Medical Oncology) Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news